ocuments subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom, Inc. undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)
[Financial tables follow]SEQUENOM, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)Three months endedMarch 31,(unaudited)20122011Revenues:Genetic analysis product sales and services
$
,140$
,844Diagnostic services
4,7801,666Total revenues
14,92013,510Costs and expenses:Cost of genetic analysis product sales and services anddiagnostics services
9,4785,013Gross Margin
5,4428,497Selling and marketing
9,7576,060Research and development
12,66310,722General and administrative
7,3504,838Total operating expenses
29,77021,620Loss from operations
(24,328)(13,123)Other (loss) income, net
(123)404Loss before income taxes
(24,451)(12,719)Income tax (expense) benefit
(2)49Net loss
$
(24,453)$
(12,670)Net loss per share, basic and diluted
$
(0.22)$
(0.13)Weighted average shares outstanding, basic and diluted
110,51298,929
SEQUENOM, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands except for par value and share information)March 31,December 31,20122011Assets:
(unaudited)(audited)Cash, cash equivalents, marketable securities
<
'/>"/>SOURCE Sequenom, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1.
Sequenom, Inc. Announces Date of Third Quarter 2011 Financial Results and Conference Call2.
Neuland Labs Reports Financial Results For Fiscal Year 20123.
Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results4.
GP Strategies Reports Strong First Quarter 2012 EPS of $0.235.
Cardinal Health Reports Third-Quarter Results6.
Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results7.
Nektar Therapeutics Reports Financial Results for the First Quarter of 20128.
Neurocrine Biosciences Reports First Quarter 2012 Results9.
CVS Caremark Reports Record First Quarter Results10.
National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month11.
Thoratec Reports First Quarter 2012 Results